EGFR and non-small cell lung carcinoma: Among 389 patients with EGFR-positive NSCLC, 18 (4.6%) received neoadjuvant EGFR tyrosine kinase inhibitors (TKI) and 11 (2.8%) received adjuvant EGFR TKI.